Although amylin was discovered decades ago, its importance in everyday clinical practice has long been underestimated. New pharmacological developments are increasingly bringing amylin into the focus of diabetes and obesity therapy, and amylin analogs, some of which have already passed phase 3 clinical trials, are now among the most promising approaches in overweight and obesity pharmacotherapy.
Autoren
- Dr. Stephanie Niklaus
- Prof. Dr. med. vet. Thomas A. Lutz
Publikation
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- Pancreatic Cancer
Innovative early detection with a focus on liquid biopsy and AI
- Cervical Cancer
HPV prevention, screening innovation and sentinel lymph node biopsy
- Polypharmacy: use of eHealth tools in Switzerland
Survey study in primary care
- From symptom to diagnosis
Abdominal pain – Prostate abscess
- Asthma during pregnancy
Up to 40% suffer worsening of symptoms during pregnancy
- From symptom to diagnosis
Complicated renal cysts
- Atrial fibrillation
Anticoagulation after catheter ablation – for how long?
- Wound treatment and dermal defect coverage